5-Aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1193-1202

  Miyoshi, Jun ^a   Yajima, Tomoharu ^a   Shimamura, Katsuyoshi ^a   Matsuoka, Katsuyoshi ^a   Okamoto, Susumu ^a   Higuchi, Hajime ^a   Funakoshi, Shinsuke ^a   Takaishi, Hiromasa ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

15 hydroxyprostaglandin dehydrogenase; 5 aminosalicylic acid; Colorectal cancer; Cyclooxygenase 2; HT 29 cells

Indexed keywords

1,2 DIMETHYLHYDRAZINE; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 5 ACETAMIDOSALICYLIC ACID; CYCLOOXYGENASE 2; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE C H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; HT29 CELLS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MESALAMINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84859946347     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994. (Pubitemid 24294584)
2. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998. (Pubitemid 28418937)
3. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
4. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D and Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8: 289-293, 2002. (Pubitemid 34250108)
5. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F and van Stolk RU: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899, 2003. (Pubitemid 36297997)
6. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G and Schilsky R: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890, 2003. (Pubitemid 36297996)
7. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD and Levin B: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885-895, 2006. (Pubitemid 44315981)
8. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB and Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884, 2006. (Pubitemid 44315980)
9. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S and Morton DG: A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674-1682, 2006. (Pubitemid 44958508)
10. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N and Wittes J: Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114: 1028-1035, 2006. (Pubitemid 44358879)
11. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA and Baron JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005. (Pubitemid 40365350)
12. Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535, 2001. (Pubitemid 32234798)
13. Bernstein CN, Blanchard JF, Kliewer E and Wajda A: Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854-862, 2001. (Pubitemid 32173312)
14. van Staa TP, Card T, Logan RF and Leufkens HG: 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54: 1573-1578, 2005. (Pubitemid 41531774)
15. Velayos FS, Terdiman JP and Walsh JM: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345-1353, 2005. (Pubitemid 40904360)
16. Jess T, Loftus EV Jr., Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P and Sandborn WJ: Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 102: 829-836, 2007. (Pubitemid 46496613)
17. Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA and Rubin DT: 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 13: 367-371, 2007. (Pubitemid 46668239)
18. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I and Schmiegel W: Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24: 443-451, 2003. (Pubitemid 36432639)
19. Fina D, Franchi L, Caruso R, Peluso I, Naccari GC, Bellinvia S, Testi R, Pallone F and Monteleone G: 5-Aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. Eur J Cancer 42: 2609-2616, 2006. (Pubitemid 44442942)
20. Luciani MG, Campregher C, Fortune JM, Kunkel TA and Gasche C: 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 132: 221-235, 2007. (Pubitemid 46108738)
21. Koelink PJ, Mieremet-Ooms MA, Corver WE, Wolanin K, Hommes DW, Lamers CB and Verspaget HW: 5-Aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes. Inflamm Bowel Dis 16: 379-389, 2010.
22. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F and Monteleone G: Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 75: 668-676, 2008.
23. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, Zhou X, Liu D, Rerko RM, Willis J, Dawson D, Tai HH, Barnholtz-Sloan JS, Newman RA, Bertagnolli MM and Markowitz SD: 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA 106: 9409-9413, 2009.
24. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K and Markowitz SD: 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 17468-17473, 2004. (Pubitemid 39657428)
25. Chi X, Freeman BM, Tong M, Zhao Y and Tai HH: 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal antiinflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys 487: 139-145, 2009.
26. Narushima S, Itoh K, Mitsuoka T, Nakayama H, Itoh T, Hioki K and Nomura T: Effect of mouse intestinal bacteria on incidence of colorectal tumors induced by 1,2-dimethylhydrazine injection in gnotobiotic transgenic mice harboring human prototype c-Haras genes. Exp Anim 47: 111-117, 1998. (Pubitemid 128439299)
27. Saitoh A, Kimura M, Takahashi R, Yokoyama M, Nomura T, Izawa M, Sekiya T, Nishimura S and Katsuki M: Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5: 1195-1200, 1990.
28. Reagan-Shaw S, Nihal M and Ahmad N: Dose translation from animal to human studies revisited. FASEB J 22: 659-661, 2008. (Pubitemid 351348146)
29. Miyoshi J, Yajima T, Okamoto S, Matsuoka K, Inoue N, Hisamatsu T, Shimamura K, Nakazawa A, Kanai T, Ogata H, Iwao Y, Mukai M and Hibi T: Ectopic expression of blood type antigens in inflamed mucosa with higher incidence of FUT2 secretor status in colonic Crohn's disease. J Gastroenterol 46: 1056-1063, 2011.
30. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D and Markowitz SD: 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 103: 12098-12102, 2006. (Pubitemid 44215817)
31. Moore AE, Greenhough A, Roberts HR, Hicks DJ, Patsos HA, Williams AC and Paraskeva C: HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis 30: 1796-1804, 2009.
32. Markowitz SD and Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460, 2009.
33. Brown JR and DuBois RN: COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855, 2005. (Pubitemid 46179475)
34. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J and Lauritsen K: Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 31: 1271-1276, 1990.
35. Luo F, Poulogiannis G, Ye H, Hamoudi R, Zhang W, Dong G and Arends MJ: Mutant K-ras promotes carcinogen-induced murine colorectal tumourigenesis, but does not alter tumour chromosome stability. J Pathol 223: 390-399, 2011.
36. Schmiegel W, Pox CP and Reiser M: German 5-ASA Polyp Prevention Study Group (GAPPS): Effect of 5-aminosalicylate (5-ASA) on the recurrence rate of sporadic colorectal adenomas. Gastroenterology 126(Suppl 2): A-452 (AGA abstract), 2004.
37. Terdiman J, Gumm J, Kim YS, Sleisenger MH, Weinberg V, Colson S, Verghese V, Hayes A and Johnson LK: Chemoprevention of colonic polyps by balsalazide: An exploratory, doulbe-blind, placebo-controlled study. Gastroenterology 126(Suppl 2): A-388 (AGA abstract), 2004.